An interventional study of Catheter Ablation for Atrial Fibrillation in Atrial Fibrillation (AF), sponsored by Marien Hospital Herne. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Marien Hospital Herne · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 417 studies in Atrial Fibrillation with a site in Germany — 60 open to participants now, 88 under way, 4 of them phase 3. Atrial Fibrillation · Germany.
Among the 417 studies in Atrial Fibrillation with a site in Germany, this one is the 119th largest by planned enrollment of the 284 interventional ones that give a count, is one of 13 that started in 2026, is one of 166 with no phase, reaches primary completion later than 50 of the 87 other live ones, and was the 415th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →60 of the 417 studies in Atrial Fibrillation with a site in Germany are open now. Recruiting first, the newest first:
Technical University of Munich · Sites in Germany
Ages 18–99
St. Josefs-Hospital Wiesbaden GmbH · Sites in Germany
Ages 18+
Hospital Universitari Vall d'Hebron Research Institute · Sites in Germany, Belgium, Italy and 3 more countries
Ages 18+
Bayer · Sites in Germany, United States, Belgium and 5 more countries
Ages 18–85
Asklepios proresearch · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
417 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 44 · Phase 4 51
First in 2000; this study’s year is marked. 13 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 268 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 200 across the 284 interventional studies, 515 across the 131 observational. Of the 289 that completed or were terminated, 92 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
214 of 417 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Marien Hospital Herne as lead sponsor.
Marien Hospital Herne has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
28 of the studies in Atrial Fibrillation with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT05005949Medtronic Cardiac Ablation SolutionsSTOP Persistent AF PAS | 2026-12 |
| NCT05557526Evangelical Hospital DüsseldorfOptimizing Quality of Life by Improved Patient Expectation Following Atrial Fibrillation Catheter Ablation | 2026-12 |
| NCT07429214Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF | 2026-12-30 |
| NCT07428564Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE PRO Software in Participants With PsAF | 2026-12-30 |
Add all 28 to your calendar (.ics) → With an account.
Among the 417 studies in Atrial Fibrillation with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Comparison of single-shot PFA systems with focal dual-energy (PFA/RF) in patients at high risk of atrial fibrillation recurrence.
Catheter ablation via pulmonary vein isolation (PVI) is an established therapy for symptomatic paroxysmal and persistent atrial fibrillation. In recent years, pulsed-field ablation (PFA) has emerged as an innovative ablation technology. Unlike thermal ablation using radiofrequency or cryoablation, PFA relies on irreversible electroporation of the cell membrane, thereby enabling the selective ablation of cardiomyocytes while largely sparing adjacent structures such as the esophagus, phrenic nerve, and pulmonary veins. Clinical studies and registry data have demonstrated high efficacy and a favorable safety profile for PFA.
Various catheter systems are now available for performing PVI via PFA. These include single-shot systems, which facilitate rapid pulmonary vein isolation through a standardized and efficient workflow. Additionally, focal dual-energy catheters have been developed that combine pulsed-field ablation and radiofrequency ablation within a single catheter. These systems allow for tailored lesion delivery using electroanatomical mapping systems and may offer advantages, particularly in cases of complex anatomy or additional arrhythmogenic substrate.
Both single-shot and focal dual-energy systems have demonstrated high acute success rates and promising clinical outcomes in studies to date. However, there are currently no direct, prospective, randomized comparisons between the two ablation strategies. In particular, it remains unclear whether there are differences between the two approaches regarding long-term freedom from atrial arrhythmias, procedural efficiency, or safety.
Patients with persistent atrial fibrillation and those with a high comorbidity burden face an increased risk of atrial arrhythmia recurrence despite successful pulmonary vein isolation. While single-shot systems enable a standardized, rapid, and reproducible ablation procedure, focal dual-energy systems-due to their greater flexibility-may offer advantages in cases of complex anatomy and for individually tailored ablation strategies.
To date, there are no randomized clinical trials directly comparing these two ablation approaches. In particular, there is a lack of prospective data regarding patients at high risk for atrial arrhythmia recurrence. This study aims to bridge this evidence gap by investigating whether ablation using single-shot PFA is non-inferior to ablation using a focal dual-energy catheter in terms of clinical efficacy in patients at high risk of recurrence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Symptomatic atrial fibrillation:
CHA2DS2VA score ≥ 2, ≥ 1 cardioversion in the last 6 months or Left atrial (LA) diameter ≥ 45 mm
o or persistent atrial fibrillation (≥ 1 episode in the last 6 months)
Exclusion Criteria:
Procedure: Catheter Ablation for Atrial Fibrillation
Procedure: Catheter Ablation for Atrial Fibrillation
PFA-based Catheter Ablation for Atrial Fibrillation (PFA single shot vs. focal dual-eregy)
Freedom from atrial arrhythmias during follow-up
Rate of participants with freedom from atrial arrhythmias (atrial fibrillation, atrial flutter, atrial tachycardia) during follow-up, excluding the blanking period
Time frame: 365 days, excluding the blanking period
Freedom from atrial fibrillation/atrial tachycardia
Rate of participants with freedom from atrial fibrillation and rate of participants with freedom from atrial flutter or atrial tachycardia) during follow-up, excluding the blanking period
Time frame: 365 days, excluding the blanking period
First-pass isolation rate and acute PVI success
Rate of first-pass isolation of the pulmonary veins as well as rate of acute procedural success of the PVI
Time frame: Day of the ablation (periprocedural)
Procedural durations
Total procedural time, fluoroscopy time, LA dwell time
Time frame: Day of the procedure (periprocedural)
Correlation between procedural parameters and clinical efficacy
Correlation between procedural parameters (first-pass isolation rate, acute procedural success rate, total procedural time, fluoroscopy time) with clinical efficacy (rate of freedom from atrial arrhythmias (AF, AFL, AT)) during follow-up, excluding the blanking period
Time frame: 365 days, excluding the blanking period
Electroanatomical evaluation in the event of potential re-ablation
In the event of a potential re-ablation, the rate of durable PVI will be assessed
Time frame: day of the potential re-ablation (periprocedural)
Patient-reported outcome measures (PROMs)
AFEQT questionnaire
Time frame: 365 days, excluding the blanking period
Occurrence of serious adverse events
Time frame: 365 days
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Aug 2027, 10 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 10 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.